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Abstract.  We have defined the structure of the Os- 
teoclast Functional  Antigen (OFA) by immunological 
and biochemical means.  OFA is an abundant surface 
antigen  in human and animal osteoclasts and has been 
characterized previously by monoclonal antibodies 
13C2 and 23C6, one of which mimicks the inhibitory 
activity of calcitonin on osteoclastic bone resorption. 
By the following criteria we show that OFA is a mem- 
ber of the integrin  family of extracellular matrix 
receptors and is identical,  or at least highly related,  to 
the vitronectin receptor (VNR) previously isolated 
from placenta and melanoma cells.  Immunoprecipita- 
tion analysis demonstrates that OFA from osteoclasts 
and a monkey kidney cell line Vero is a heterodimeric 
molecule of 140 kD (ct chain) and  85 kD (/3 chain) 
under nonreducing  conditions; on reduction at least 
one low molecular mass (a')  species (of ~  30-kD size) 
is released,  resulting  in a  120/lO0-kD dimer.  Immuno- 
blots of OFA isolated from osteoclasts and Vero cells 
and VNR purified from placenta and probed with het- 
erosera to OFA and monoclonal antibodies to platelet 
gpllla  (VNR/3 chain)  show immunological  cross- 
reactivity between the ot chains of OFA and VNR and 
the use of gpl 1  la as a ~  chain by both.  OFA from 
Vero cells binds to an Arg-Gly-Asp containing peptide 
(GRGDSPPK) isolating a heterodimer recognized by 
anti-OFA monoclonal antibodies,  13C2 and 23C6.  Im- 
munohistochemical analysis showed a  similar tissue 
distribution in humans  for the antigen recognized by 
anti-OFA antibodies, a monoclonal antibody, LM142, 
raised to melanoma VNR, polyclonal antibodies to the 
placental VNR and a monoclonal antibody to the 
presumptive VNR/~ chain,  platelet glycoprotein  1  l la. 
Finally,  NH2 terminal  amino acid sequencing showed 
that the amino-terminus  of the monkey ot chain was 
identical  in the  12 assigned residues to that of human 
VNR ot chain.  The/3 chain sequence of OFA differed 
at least  1 (and up to 4) positions from platelet gpl 1  la 
(VNR/3) in the first  18 amino acids sequenced. 
These, and other,  data provide the first indication of a 
function for the VNR and suggest that cell-cell and 
cell-extracellular matrix  interactions  involving inte- 
grins may play an important  role in bone physiology. 
O 
~rEOCLASTS (OCs)' are multinucleate giant cells with- 
in bone and are the major cellular effectors of bone 
resorption (for reviews,  see Marks,  1983; Nijweide 
et al.,  1986; Vaes,  1988).  A variety  of experimental  data 
have shown conclusively that the OC is derived from a bone 
marrow  cell  reaching  the bone surface via a blood borne 
mononuclear precursor.  These include experimental  parabi- 
osis (G6thlin  and Ericsson,  1973),  quail-chick chimearas 
(Jotereau  and Le Douarin,  1978), the cure by bone marrow 
transplantation  of the abnormality in bone resorption seen in 
congenital osteopetrosis (Walker, 1975), and the coisolation 
of OC precursors with those of myeloid colony forming cells 
(Scheven et al.,  1986).  Less conclusive is the nature  of its 
I. Abbreviations  used in this paper: OC, osteoclast; OFA, osteoclast func- 
tional antigen; OGP, octyl glycopyranoside; VLA, very late antigen; VNR, 
vitronectin receptor. 
stem cell and route and control of its differentiation.  Thus a 
major point of contention  has been over the exact relation- 
ship between the OC and cells of myeloid lineage (discussed 
in  Nijweide et al.,  1986;  Horton,  1988).  Since  OCs are 
known to be formed by cell fusion, they have conventionally 
been considered to be a specialized  form of skeletal  mac- 
rophage,  analogous  to the inflammatory  macrophage  poly- 
karyon (Chambers,  1978). However, although  they share a 
number of properties, they differ in several important  ways. 
For example,  terminally  differentiated  macrophages  do not 
have calcitonin  receptors (Nicholson et al.,  1986) nor do 
they respond to calcitonin  (Chambers and Magnus,  1982), 
and they are incapable of resorbing inert bone in vitro (Cham- 
bers et ai., 1984; Chambers and Horton, 1984), all of which 
are functional hallmarks of  the OC. These differences do not, 
however, preclude a common ancestry since terminal  differ- 
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count for such disparities. Thus, the stage at which OCs and 
other haemopoietic cells are related, whether only distantly 
as  suggested by some transplantation (Loutit and Nesbit, 
1982) and phenotypic (Horton et al.,  1984,  1985a)  studies 
or more closely at the stage of an immature monocyte (Bur- 
ger et al.,  1982),  is not known. 
In an attempt to resolve this question, several  groups in- 
cluding our own (Horton et al., 1985b; Oursler et al., 1985; 
Nijweide et al.,  1985) have produced mAbs specific for OC 
antigens for use in the analysis of OC differentiation. Anti- 
bodies 13C2 and 23C6 (Horton et al.,  1985b)  were raised 
to a  human tumour,  the giant cell tumor of bone or os- 
teoclastoma, which is uniquely enriched with OCs (Fig. 1). 
These two mAbs were shown subsequently to have a high de- 
gree of specificity for human OCs (Horton et al.,  1985b), 
generally failing to react with other haemopoietic or bone 
cells including those of the mononuclear phagocyte system; 
to be widely expressed on nonhuman mammalian and avian 
OCs (Horton and Chambers,  1986);  to be developmentally 
regulated during embryogenesis, appearing early on preosteo- 
clasts adjacent to bone anlagen (Simpson and Horton, 1989); 
and to mediate inhibitory effects on osteoclastic bone resorp- 
tion in vitro (Chambers et al., 1986), suggesting a functional 
role in bone for the molecule that the mAbs recognize. 
In this paper we describe the characterization of the mole- 
cule recognized by mABs  13C2  and 23C6,  the osteoclast 
functional antigen (OFA) (Davies et al.,  1988) and demon- 
strate that it is a member of the family of tissue-specific ex- 
tracellular matrix receptors  (Ruoslahti and Pierschbacher, 
19~q7) termed integrins (Hynes, 1987),  showing a high de- 
gree of homology, or identity, to the vitronectin receptor 
(Pytela et al., 1985b; Suzuki et al., 1986 and 1987; Fitzger- 
ald et al.,  1987b).  OFA thus forms a hitherto unrecognized 
class of receptor on OCs that is likely to have functional im- 
portance in the regulation of bone resorption. 
Materials and Methods 
Cell Lines and 1issues 
The Vero monkey kidney cell line (Fig.  1 a) was maintained in log phase 
growth  by twice weekly  passage  and  growth  in RPMI  1640  (CRPMI) 
medium containing  10% FCS, glutamine,  and antibiotics. 
Platelets  were prepared  from whole  blood  of normal  volunteers,  an- 
ticoagulated  with Acid-Citrate-Dextrose  (ACD) solution  and  isolated  by 
differential centrifngation. 
Tissues  for immunohistology  or biochemical  analysis  were  obtained 
from surgical removal (samples of giant cell tumor of bone [Fig. I b]), par- 
turition (full term placental), postmortem (kidney), or following therapeutic 
abortion (fetal bone). All tissues were obtained with ethical committee ap- 
proval, and, in the case of fetal material, the recommendations of the Peel 
Report were followed. Tissues for biochemical studies were snap frozen and 
stored dry in liquid nitrogen until use. Tissues for immunohistoiogy wore 
snap frozen in OCT (TissueTec Laboratories Inc., IN) embedding medium 
and stored in liquid nitrogen until use. Human fetal bones were dissected 
from 12-16-wk fetuses, cleaned of excess connective tissue, chopped, and 
tissue imprints prepared as previously described (Horton et ai., 1985a,c); 
these were subsequently air dried, fixed in dry acetone for 10 rain and stored 
frozen at  -20"C for use within  1 mo of preparation. 
Antibodies 
Monoclonal antibodies to giant cell tumour of bone, 13C2 and 23C6, as de- 
scribed  (Horton  et al.,  1985b) were  used as tissue  culture  supernatants 
throughout the study. Some features of their immunohistological (Horton 
et al.,  1985b; Warwick et al.,  1987) and functional reactivity (Chambers 
et al.,  1986) have been reported previously. Antibody 5/9 (Horton et al., 
1985b) was used as an lgGl isotype control for experiments using mono- 
clonals  13C2 and 23C6. 
Monoclonal antibodies to platelet gpllla (VI-PLI2;  Dr. Knapp, Univer- 
sity of Vierma, Vienna) and gpllb/llla complex (P256; Dr. Hol~  , I. C. R. F., 
London) were gifts of their originators and have previously been character- 
ized in an international workshop (Hogg and Horton,  1987). 
Monoclonals LMI42 and LM609 (gift of  Dr. Cheresh, Research Institute 
of Scripps Clinic, La Joila, CA) were raised against the M21 melanoma cell 
line and  characterized  as  reacting  with  the vitronectin  receptor  (VNR) 
(Cheresh and Harper,  1987; Cberesh and Spiro, 1987). A polyelonal rabbit 
antiserum raised against Arg-Gly-Asp peptide affinity-purified human pla- 
cental VNR (Suzuki et al., 1986) was kindly provided by Dr. Ruoslahti (La 
Figure 1. (a) Immunofluorescence photomicrograph of acetone-fixed Vero monkey kidney cells stained with mAb 23C6 showing membrane 
and cytoplasmic distribution of OFA. (b) Wax-embedded section of formalin-fixed osteoclastoma (giant cell tumor of bone) stained by in- 
direct immunoperoxidase technique with rat polyclonal antiserum to immunoaflinity purified OFA heterodimer.  Note that the large mul- 
tinucleate OCs show a surface membrane distribution of product (arrowhead)  whereas the majority of mononuclear cells (stromal cells 
and  infiltrating leucocytes) are negative. Bar,  100  #tm. 
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Pharmaceuticals  Inc.  (San Diego, CA). 
Rat and rabbit polyclonal antibodies were prepared to the OFA antigen, 
purified as below (Krissansen et al., 1986). The rabbit and rat (named FRI) 
heterosera showed biochemical  and immunological  characteristics  similar 
to mAbs 13C2 and 23C6 and the polyclonal antiplacental VNR sera; they 
were used without further  purification. 
lmmunohistology 
lmmunostaining of frozen sections of human tissues (giant cell tumour of 
bone, placenta, and kidney), cytospin preparations of Vero monkey kidney 
cells, or human fetal bone imprints, was performed on acctone-fixed mate- 
rial  using  the  indirect  immunofluorescence  or  immunoperoxidase  tech- 
niques as previously described  (Horton  et al.,  1984, 1985b). 
Purified Proteins 
VNR purified by RGD peptide affinity chromatography (Pytela et ai., 1987) 
was a kind gift of Dr. E. Ruoslahti. 
Cell and Protein Labeling Techniques 
Confluent cultures of 107 Vero ceils were metabolically labeled by incuba- 
tion  for 2  h  with  0.2  Ci/ml [35S]methionine (Amersham  International, 
Amersham,  UK)  in  methionine-free  medium  and  chased  for 68 h  with 
methionine-replete  RPMI 1640 growth medium containing  10% FCS. 
A cell suspension of  giant cell tumor of  bone containing a high proportion 
of OCs was labeled by lactoperoxidase catalysed  t251-iodiuation (IMS.30, 
Amersham International) (Hubbard and Cohn,  1972). FPLC size-fraction- 
ated, partially purified OFA dimer (see below) was iodinated by the chlora- 
mine T method (Hunter  and Greenwood,  1962). 
Metabolically and surface iodinated cells were solubilized by lysis on ice 
in NP-40 buffer (20 mM Hepes, pH 7.2, 50 mM NaCI, 0.3 M sucrose,  3 
mM MgCI2, 1 mM CaCI2, 0.5% NP40, 1 mM PMSF), nuclear and cellu- 
lar debris removed by centrifugation and the lysate precleared by the addi- 
tion of 50 #1 of a  10%  solution of formalin-fixed Staphylococcus  aureus 
Cowan A strain. Primary antibodies (13C2, 23C6, 5/9, P256; 200 #1 culture 
supernatant or 10 #1 ascitic fluid) were coincubated for 90 rain on ice before 
isolation of the antibody-antigen  complexes with S. aureus precoated with 
rabbit  anti-mouse  IgG serum  (Dako  Corp.,  Santa  Barbara,  CA).  The 
S. aureus pellet was retrieved by centrifugation and washed thrice in lysis 
buffer to  reduce  background  contamination.  Iodinated  (mAb  or peptide 
affinity) purified OFA cd/5 heteroimer was treated similarly. Analysis of the 
immunoprecipitates was by SDS-PAGE (Laemmli,  1970) under nonreduc- 
ing or reducing (5 % vol/vol 2-mercaptoethanol) conditions followed by au- 
toradiography;  [35S]methionine gels were subjected to fluorography (Bow 
her and Laskey, 1974). 
Western blotting 
Lysates of  giant cell tumor of bone, platelets and Vero cells; immunoaffinity- 
purified  OFA  and  RGD-purified  placental  VNR  (Pytela  et  al.,  1987); 
13C2/23C6 or P256 immunoprecipitates  of platelets and Vero cells were 
electrophoresed in 7.5 % SDS-PAGE under reducing conditions and the pro- 
reins transferred onto 0.45-#m pore size nitrocellulose membrane (Schleicher 
&  Schuell  Inc., Keene,  NH) by semi-dry  electroblotting  (200 mA,  1 h, 
using Sartorius apparatus  and manufacturer's  stated conditions).  Comple- 
tion of transfer was monitored by silver staining of  the gel (Morrissey, 1981) 
and  transfer of Cooruassie  blue-stained  molecular  mass markers  (Sigma 
Chemical Co., St. Louis, MO). Nonspecific binding to the membranes was 
blocked by preincubation with 1% gelatin (Sigma Chemical Co.).  Antigen 
was localized by incubation with rat (FRI) or rabbit anti-OFA; bound anti- 
body was visualized by sequential incubation with biotinylated anti-species 
Ig  reagents,  peroxidase-~ronjugated avidin with  color development  using 
4-chloro-l-naphthol. 
Peptide AJ~inity Chromatography of the Vero  Receptor 
Vero receptor  was isolated according to previously established techniques 
(Pytela et al.,  1985a,b).  5  x  107 surface-iodiuated  Veto cells were lysed 
at 4°C in 1 ml buffer (PBS pH 7.4 containing 1 mM CaCi2, 1 mM MgCI2, 
200 mM octylglycopyranoside  [OGP], and 3 mM PMSF).  The lysate was 
centrifuged to remove cellular debris, incubated overnight at 4°C with 1 ml 
of  GRGDSPPK-Sepharose; the peptide column was made by reacting 20 mg 
acetylated  GRGDSPPK  peptide  (kindly  provided  by  Dr.  J.  Rothbard, 
I.C.R.E, London) under standard conditions with 1 ml of CNBr-Sepharose 
(Sigma Chemical Co.). The column was then washed with 5 ml PBS con- 
taining 50 mM OGP,  1 mM PMSF followed by 2 ml of buffer containing 
1 mg/ml free GRGDSPPK peptide. Fractions of 0.5 rnl were collected and 
the ethanol-precipitated protein from 100-/~1 aliquots of each fraction were 
anlayzed by electrophoresis on 11% SDS-polyacrylamide gels under reduc- 
ing conditions. 
OFA .  and ~ Chain Purification and NH2-terminal 
Amino Acid Sequencing 
The OFA dimer was purified (Krissansen ct al., 1986) from Veto cells using 
mAb affinity chromatography  with both mAbs 13C2 and 23C6, linked to 
Sepharose CL4B (Pharmacia Fine Chemicals,  Uppsala) at pH 7.0 using the 
method  of Kumel et al.  (1979).  The two monocionals,  which  recognize 
different epitopes on the same mot~ule, were combined as they were found 
to markedly increase antigen yield in ~tive  affinity chromatography 
when used together. The isolated proteins "were electrophoresed  in a non- 
reduced 7.5% polyacrylamide/SDS  gel with 1 ~1M thioglycollate added to 
the upper  buffer reservoir.  The separated  ¢  and  ~ chains of OFA were 
visualized by exposure to 4 M Na acetate (Higgins and Dahmus,  1979) cut 
from the gel and passively eluted into 50 mM ammonium bicarbonate pH 
8.0, 0.1% SDS, 0.1 mM DTT buffer. The proteins  were then reduced and 
alkylated with 10 mM DTT/22 mM iodoacetamide (Vehxdal et al., 1968) 
and recovered by precipitation with  I0% trichloracetic  acid.  The ~ chain 
was dissolved in 6 M guanidine HCI in 0.1 M KH2PO4, pH 4.5,  purified 
by FPLC on two Superose  12 columns  in series eluted with 70%  formic 
acid.  Two samples of 9 ~tg of each protein,  as determined  by amino acid 
analysis (6300 analyser; Beckman Instruments,  Palo Alto, CA) were sub- 
jected to Edman degradation using a sequencer (477A; Applied Biosystems, 
Inc., Foster, CA) equipped with a 120 A on line phenyithiohydantoin amino 
acid analyzer. 
Results 
lmmunoprecipitation Analysis of the Antigen 
Recognized by Anti-OFA Monoclonal Antibodies, 
13C2 and 23C6, in 0(7 and the Vero Cell Line 
Monoclonal antibody 23C6 immunoprecipitates a heterodi- 
meric molecule (Fig.  2,  lane 4)  from human OC derived 
Figure  2.  Immunoprecipita- 
tion analysis, with mAbs 13C2 
and 23C6, of human OCs and 
the monkey  cell line Veto. Lane 
I, chloramine T iodinated OFA 
antigen (star) immunoatfifflty 
purified with 13C2 and 23(=6 
mAbs  from the  Veto kidney 
cell  line.  BSA  was  used  to 
quench the iodination reaction 
and is indicated (arrowhead). 
Lane 2, molecular mass mark- 
ers (from top to bottom,  200, 
92.5, 69, 4~ and 30 kD). Lanes 
3 and 4, immunoprecipitation 
analysis of iodinated osteoclasts 
from a giant cell Umlor  of  bone, 
using mAb 23C6 (star) (lane 
4) or negative control antibody, 
P256,  to  platelet  gpllb/llla 
complex (lane 3). All samples 
were reduced and subjected to 
10%  SDS-PAGE. 
Davies et ai. Integrin Receptor of Osteoclasts  1819 Figure 3. Characteristics of  OFA from the Vero cell line under non- 
reducing and reducing conditions. Lanes 1 and 3, negative control 
immunoprecipitations  using  mAb 5/9 of the  same IgG1 isotype. 
Lanes 2 and 4,  13C2 (or 23C6, not shown) mAb immunoprecipi- 
tated OFA from [35S]methionine metabolically labeled Veto cells 
run under nonreducing (lane 2) and reducing (lane 4) conditions. 
Lane 5, FPLC size-fractionated Vero antigen was prepared under 
nonreducing conditions, iodinated, immunoprecipitated with anti- 
OFA antibody, and analyzed by SDS-PAGE under reducing condi- 
tions.  Minor  protein  species  released  from OFA upon reduction 
(star). All proteins were analyzed by 10% SDS-PAGE; the position 
of the 92.5 kD molecular  mass marker is indicated (caret). 
from giant cell tumor of bone (Fig.  1 b). Similar results (not 
shown, but see Fig. 3) were obtained with 13C2 monoclonal. 
As predicted  from immunohistology,  (Fig.  1 a),  a  similar 
sized dimer is isolated from the Vero monkey kidney cell line 
(and the ACHN human renal line, not shown), which showed 
high levels of OFA expression (Fig. 2, lane/) using the same 
antibodies. Under reducing conditions the molecular sizes of 
the two chains isolated from OC and kidney are of 120 kD 
and 100 kD apparent molecular mass. The terminology used 
in this paper calls the higher molecular mass species the tx 
chain and the lower the/3 chain of OFA. 
Because of the difficulty in obtaining large numbers of OC, 
even from bone tumors, the Vero monkey kidney cell line 
was used as the source of antigen for the primary biochemi- 
cal and immunochemical characterization of OFA. 
A  particular feature of the OFA molecule is its behavior 
on reduction.  Fig. 3 (lane 2) shows that the mAbs 13C2 (or 
23C6) recognize an t~ chain of 140 kD and/~ chain of 85 kD 
in the Vero cell line when electrophoretically separated un- 
der nonreducing conditions. Upon reduction (Fig. 3, lane 4) 
the molecular mass of the c~ chain falls to  120 kD and the 
/3 chain increases to  100 kD. Reduction is accompanied by 
the  release of low  molecular  mass peptides  (ct' chain)  of 
,,o 30-kD size. This is shown in Fig. 3 (lane 5) where the OFA 
c~ and/~ chain complex has been immunopurified under non- 
reducing conditions,  size fractionated by FPLC and finally 
separated  electrophoretically  under  reducing  conditions. 
Shifts in size upon reduction are characteristic of members 
of the integrin receptor family; for example, platelet gpllb/ 
11 la complex and the vitronectin and fibronectin receptors 
(Pytela et ai.,  1986). 
Demonstration that the 13 chain of OFA Is 
lmmunologicaUy Cross-reactive with "Platelet" gp111a 
Previous immunohistological studies (Horton, 1986; Athan- 
asou et al., 1986) have demonstrated that OCs express gpl 1  la, 
but not other platelet-specific membrane proteins. Molecular 
cloning (Fitzgerald et al.,  1987a; Rosa et ai.,  1988) and ira- 
Figure 4.  Demonstration of immunological iden- 
tity of the/3 chain of OFA and platelet gpl 1  la. A, 
Immunoblot analysis of whole platelet lysate (lane 
2), Veto surface membranes (lane 3), and immu- 
noaltinity-purified Vero antigen (lane 4). Proteins 
were  electmphoresed  through  7.5% polyacryl- 
amide gel under reducing conditions, electropho- 
retically transferred onto nitrocellulose paper and 
probed with normal rat serum (lane 1 ) or a rat bet- 
eroserum (FRI) raised against purified OFA that 
reacts with both o~ and/~ chains of OFA. Bound an- 
tibody  was detected  using  biotinylated  anti-rat- 
IgG  and horseradish peroxidase conjugated avidin. 
Positions of ot and/3 bands (star). B, Immunopre- 
cipitation of surface-iodinated Vero cells (lanes 5 
and 6) and platelets (lanes 7and 8) with antiplate- 
let gpl lb/l 1  la, P256, (lanes 5 and 8) and anti-OFA 
mAbs (lanes 6and 7) run out on SDS-PAGE  under 
nonreducing conditions in the presence of EDTA. 
The position of  the 92.5-kD molecular mass mark- 
er  is  indicated  (caret).  C,  immunoblot  analysis 
using rat antiserum,  FRI, of immunoprecipitates 
from Vero (lanes 9 and 10, 12 and 13), prepared 
as in B, compared with whole platelet lysate (lane 
H ), electrophoresed under reducing conditions m 
SDS-polyacrylamide  gels.  Positions  of ot and  /3 
bands (star). 
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iodinated Vero cells on GRGDSPPK-Sepharose. Surface4odinated 
Veto cells were lysed in extraction buffer, incubated overnight at 
4°C with  1 ml of GRGDSPPK-Sepharose. The column was then 
washed with PBS containing 50 mM OGP, 1 mM PMSF, followed 
by 2 ml of  column buffer containing 1 mg/ml of soluble GRGDSPPK 
peptide.  0.5-ml  fractions  were  collected,  and  the  ethanol-pre- 
cipitated protein from 100-#1 aliquots of each fraction was ana- 
lyzed on 11% SDS-PAGE under reducing conditions. The tracks 
represent the following elution fractions: A, lane 1, Vero lysate ap- 
plied to column; lane 2, column wash; lane 3, I mg/ml GRGDSPPK 
eluate. B, lanes 4 and 5, immunoprecipitation of eluted material 
with antibody  13C2 (or 23C6  not  shown) exposed for different 
times to show the ot//~  dimer (star) and low molecular mass cleaved 
peptides (square). The position of the 92.5-kD  molecular mass 
marker is indicated (caret). 
OFA Binds to an Octapeptide A Oinity Matrix That 
Contains the Arg-Gly-Asp Fibronectin Recognition 
Sequence 
The behavior of OFA on reduction and the immunological 
similarity of the OFA/5 chain to gpllla led us to postulate 
that it formed part of the family of membrane receptors that 
recognize extracellular matrix molecules containing the Arg- 
Gly-Asp (RGD) amino acid sequence, of which the platelet 
gplla/llla complex (Pytela et al., 1986) and VNR (Pytela et 
al.,  1985b) are well-characterized examples.  We analysed 
the binding of OFA antigen from Vero to an immunobilized 
synthetic  octapeptide,  GRGDSPPK,  shown  previously  to 
bind to many of the family of cytoadhesive molecule recep- 
tors (Ruoslahti and Pierschbacher, 1987) (Fig. 5). A molecu- 
lar complex, identical in size and chain structure to OFA, 
bound  to  the  peptide  column  and  was  eluted  by  free 
GRGDSPPK peptide (Fig.  5,  lane 3) but not with control 
GRGESPPK peptide; the eluate was shown to be immuno- 
logically identical to OFA by immunoprecipitation with mAbs 
13C2 (and 23C6, not shown) (Fig. 5, lanes 4 and 5). Thus 
OFA, like the VNR and platelet gpllb/llla, recognizes Arg- 
Gly-Asp-containing peptide ligands (Ruoslahti and Piersch- 
bacher,  1986 and  1987). 
Immunological Identity of OFA and Arg-Gly-Asp 
Peptide A~inity-purified Placental VNR : Western Blot 
Analysis with Polyclonal Antisera to OFA 
Polyclonal antisera made to 23C6/13C2 mAb-purified Vero 
OFA detect both the c~ and/5 chains of OFA purified from 
Vero cells (i.e., the immunogen; Fig. 6, lane 3) and VNR 
purified from placenta by RGD peptide affinity chromatogra- 
phy (Pytela et al.,  1987) (Fig. 6, lane 2); these data support 
the identity, or at least immunological similarity, of the two 
receptor molecules.  The same  sera  react with a  dimer of 
similar molecular mass derived directly from osteoclastoma 
tumor (Fig. 6, lane 4) and Vero cells (Fig. 6,  lane 5).  The 
minor differences in the mobility of the OFA bands seen in 
Fig. 6 were not consistent between experiments. Finally, and 
compatible with the/5 chain of OFA being platelet gpl 1  la 
(see earlier section), anti-OFA sera react with the/3 chain 
(gpll la) of the platelet integrin, gpl lb/ll la (lane/). 
munochemical studies (Cheresh and Harper, 1987; Ginsberg 
et al.,  1987) of the VNR have also shown that the/5 chain 
of VNR is platelet gpl lla. The similarity in size of the OFA 
/5 chain and gpl 1  la led us to investigate whether they were 
identical. Western blots of platelet and Vero cell lysates using 
a  rat heteroserum (FRI) made to purified OFA cd/5 chains 
(Fig. 4 A) (which detects OCs immunohistologically [Fig.  l 
b])  suggested  that  the two were immunologically related. 
This was proven by Western blotting immunoprecipitates of 
platelet gpl lb/l 1  la and Veto-derived OFA or//5 heterodimer 
(Fig. 4 B and C) with the heteroserum. The gpl lla chain of 
platelet gpl lb/11  la (isolated from platelets with an mAb P256, 
to gpl lb/l l la, Fig. 4 B, lane 8) was recognized by FRI antise- 
rum (Fig. 4 C, lane 12) as was the OFA u (and/5) chain from 
the Vero cell line (Fig. 4 C, lane 10) (isolated by precipitation 
with  13C2 and 23C6 mAbs,  Fig. 4 B, lane 6). 
Figure 6.  Western blot analysis 
using rabbit anti-OFA antiserum 
of platelets (lane 1), OFA/VNR 
isolated  from placenta  (lane 2) 
and the  Vero cell line (lane 3), 
and lysates of giant cell tumor of 
bone  (lane  4),  and  Vero cells 
(lane 5). Placental VNR (lane 2) 
was  purified  by  RGD-peptide 
affinity chromatography and Vero 
OFA (lane 3) using  13C2/23C6 
antibodies  (see  Materials  and 
Methods). Proteins were electro- 
phoresed through 7.5% gels un- 
der reducing  conditions. Prestained 
molecular  mass markers  (92.5 
and 69 kI)) are indicated (arrow- 
head). 
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1  2  3  4  5  6  7  S  9  10  11  12  13  14  15  16  17  18 
OFA a chain (monkey)  m  Phe  Asn  Leu  Asp  Val  Asp  Ser  Pro  Ala  Glu  Tyr  ?  Gly 
VNR a chain (human)  Phe  Ash  Leu  Asp  Val  Asp  Ser  Pro  Ala  Glu  Tyr  Ser  Gly 
OFA B chain (monkey~  Gly  Pro  Ash  lie  Cys  Thr  {Gly,/Thr)  Leu  Gly  Va~  Ser  Leu  ?  Gfn  ?  Gin  Leu  Ala 
VNR B chain (human)  Gly  Pro  Asn  lie  Cys  Thr  Thr  Arg  Gly  Val  Ser  Ser  Cys  Gin  Gin  Cys  Leu  Ale 
~  _Structural  homology with the NH2 termini  of OFA/VNRa  has been observed for gpl lb (Chafe et al.,  1986; Fitzgerald ot al., 1987b;  Poncz el al, 1987) 
r-/~-]/uu~ la (~pringer et a¢., ] ~);  Mac-IlCD1 lb (Arnaout et al., 1988); p15O/CD1  lc (Corbi et al., 1987); VLAa chains (Takada et al., 1987); fibronectin recep- 
todVLA-5 (Argraves et al., 1986). 
b. Lack of homology has been noted between OFA/VNR/~ (gp111a) and chicken integrin  Band 3 (VI_A,8) (Tamkun et al., 1986) and LFA B (CD18) (Kishimoto 
et al., 1987). 
Figure 7. Amino-terminal amino acid sequencing  of ¢~ and/3 chains of OFA. The amino-terminal  amino acid sequence of the Veto monkey 
c~ (120 kD) (a) and/~ (100 kD) (b) chains of OFA, as determined in this study, are shown in comparison with the amino-terminal  sequence 
of the human VNR (Charo et al.,  1986; Suzuki et al.,  1987; Fitzgerald et al., 1987a,b; Rosa et al.,  1988). */~8 difference  between OFA 
and VNR; ?, unclear PTH signal; (),  OFA/37 signal Gly or Thr; $, OFA/~12 and 16 amino acid assignment probable. 
Amino Terminal Sequencing of the ~ and/3 Chains of 
OFA Purifwd  from the Veto Monkey Kidney Cell Line 
Reveals Homology with the Human VNR 
We have isolated the two high molecular mass chains of OFA 
from Vero cells, analyzed their amino acid composition and 
sequenced  their  NH~-terminal  amino  acids  (Fig.  7).  Be- 
cause of the scarcity of OC-rich giant cell tumor of bone, we 
did not have the opportunity to confirm this sequence data 
from (presumed) OCs; the immunological and biochemical 
data presented herein would support our use of Vero cells as 
a reasonable alternative source of OFA for sequencing. 
Sequence from the OFA 13 chain shows a number of differ- 
ences (at least one, position 8, and up to four, positions 7, 
12, and 16 additionally; see Fig. 7) from the published se- 
quences of platelet gpl 1  la from platelets, endothelium and 
HEL erythroleukaemia cells (Charo et al., 1986; Fitzgerald 
et al., 1987a; Rosa et al., 1988). Taken with its high cysteine 
content (not shown), this data supports our immunological 
and biochemical findings (Figs. 4 and 8) that the/3 chain of 
OFA was likely to be gpll la. 
The sequence of the OFA a  chain (Fig. 7) is essentially 
identical to that of the VNR a  chain (Suzuki et al., 1986 and 
1987; Fitzgerald et al., 1987b) with an uncertain amino acid 
designation at position  12  for OFA.  In  general,  integrin 
receptor a  chain NH2-terminal  sequences are homologous 
though distinctive, particularly within the subgroups of the 
supergene family (compared in Takada et al.,  1987).  This 
contrasts with some nonintegrin adhesion receptors, for ex- 
ample the cadherins, which are identical at their NH2 ter- 
mini (Shirayoshi et al.,  1986).  These results thus strongly 
suggest that the OFA  and VNR a  chains are one and the 
same. 
A computer search has confirmed the relationship between 
the OFA/VNR c~ chain and members of the Arg-Gly-Asp 
(RGD) cytoadhesive molecule receptor family that has been 
noted by others: platelet gpllb (Charo et al., 1986; Poncz et 
al., 1987; Fitzgerald et al., 1987b),  LFA-1/CDlla (Springer 
et al.,  1985),  Mac-l/CDllb (Arnaout et al.,  1988),  p150/ 
CDllc (Corbi et al., 1987) and the very late antigen (VLA) 
chains (Takada et al., 1987), including that of  the fibronec- 
tin receptor/VLA-5 (Argraves et al., 1986) showing similari- 
ties to OFA at their NH2 termini. 
The OFA/3 chain showed a high degree of homology to 
gpllla (Fig. 7), but not to the/3 chains of the other integrin 
families: chicken integrin band 3 (the avian equivalent of the 
VLA/3 chain) (Tamkun et al.,  1986) and CD18,  the LFA 
family/3 chain (Kishimoto et al.,  1987). 
lmmunohistochemical Analysis of  Antibodies to OFA 
and VNR Reveal an Identical 7Issue Distribution 
The tissue distribution of the antigens recognized by mono- 
clonal antibodies to OFA (13C2  and 23C6,  Horton et al., 
1985b) and melanoma VNR (LM142, Cheresh and Harper, 
1987; Cheresh and Spiro, 1987) is summarized in Table I and 
illustrated in Fig.  8.  In vivo, both sets of antibodies bind 
strongly to OCs in bone tumors and fetal bone, placenta, and 
kidney (glomerulus and distal tubule) and weakly to vascular 
endothefium (not shown);  they fail to react with osteoblasts 
and bone m~ cells. A similar immunohistochemical dis- 
tribution is seen in the rabbit and chicken (mAb 23C6 only, 
Horton  and  Chambers,  1986).  Polyclonal  antibodies  to 
purified OFA raised in rat and rabbit (observations in this pa- 
per)  show a  similar tissue specificity to mAbs  13C2  and 
23C6 (data not shown; Warwick, J. and M. Horton, manu- 
script in preparation). 
Heterosera  to  RGD-purified  placental  VNR  (or  and  /3 
chain-reactive) (Suzuki et al.,  1986)  also show a  similar 
reaction to monoclonal antibodies to OFA (Table I). 
In comparison, mAb V1-PL2 (Hogg and Horton,  1987), 
which was raised against platelets and detects platelet gpl 1  la 
(OFA/VNR/3 chain, see above) reacts with a similar range 
of cell types as antibodies to OFA/VNR (Table I). Addition- 
ally, strong reactivity with cells of the platelet-megakaryo- 
cytic lineage is seen, presumably because of detection of the 
other heterodimer that uses gpllla as its/3 chain-platelet 
gpl lb/11 la. Minor differences are, however, seen in vivo (Ta- 
ble I) including stronger reactivity of V1-PL2 with vascular 
endothelium, and weak or absent staining of renal tubules 
and placenta. The basis for the variation in tissue distribution 
is at present unclear. 
Although expression of the OFA/VNR is quite restricted 
in vivo, its distribution is much more widespread if cultured 
adherent cell lines are considered. An extensive comparison 
of its expression on cell lines is outside the scope of this pa- 
per; however, it is worth commenting that though OFA/VNR 
is "absent" from osteoblasts in vivo, many in vitro osteosar- 
coma (hence osteoblast-derived) cell lines express moderate 
levels of OFA/VNR (summarized in Table I).  Indeed, the 
The Journal of Cell Biology, Volume 109,  1989  1822 Figure 8. Immunohistological  staining of OFA-expressing human tissues by the immunottuorescence  and immunopemxidase  techniques. All 
use the mAb 23C6, but equivalent results were obtained with mAbs 13C2 (Horton et al.,  1985b) and LMI42 (Cheresh el al.,  1987). (a) 
Frozen section of OC-containing giant cell tumor of bone. Membrane immunottuorescence  staining is seen on large multinucleate and some 
mononuclear cells (b). Immunofluorescence  staining of a tissue imprint from a 14-wk  gestation  human fetal long bone showing  positive staining 
of OCs. Note the absence of staining of other marrow or bone elements in this preparation. (c) Frozen section of human full-term placenta 
showing strong immunoperoxidase reaction in the syncytiotrophoblast  layer. (d) Frozen section of human kidney showing weak reaction in 
glomeruli (white arrowhead), and stronger reaction with distal renal tubules (black square). Bar, 100 #m. 
VNR ~  chain was  first purified from the MG63 osteosar- 
coma cell line (Pytela et al.,  1985b). 
Discussion 
In this paper we describe the characterization of a cell sur- 
face  (glyco)protein, OFA  (Davies  et al.,  1988),  which  is 
abundant in OCs and otherwise limited in its distribution in 
vivo to kidney and placenta. In particular, its lack of expres- 
sion  by  cells  of  the  mononuclear  phagocyte  system  is 
noteworthy (Horton et al., 1985b). Several lines of evidence, 
both biochemical and immunological, point to OFA belong- 
ing to the family of extracellular matrix receptors termed 
variously integrins or cytoadhesins (Hynes, 1987; Ruoslahti 
and Pierschbacher, 1987; Ginsberg et al., 1988). First, OFA 
consists  of an  ~//~  heterodimeric  (glyco)protein complex 
(Fig. 2) with a low molecular mass disulphide bond linked 
or' chain (or possibly two chains) (Figs. 2 and 3) released on 
reduction. Second, the complex binds to a fibronectin con- 
sensus sequence-derived (Pierschbacher and Ruoslahti, 1984) 
Arg-Gly-Asp (RGD)-containing affinity matrix and can be 
eluted with cognate peptide (Fig. 5). Third, Western blots of 
heterodimers isolated from OCs, the Vero cell line, placenta, 
and platelets show that the ~ chain of OFA is immunologi- 
cally cross-reactive with platelet gpl 1  la and the ot chain with 
the ~  chain of VNR (Figs. 4 and 6). Fourth, NH2-terminal 
amino-acid  sequencing of OFA  ot  and  /$  chains  (Fig.  7), 
purified from the Vero primate kidney cell line, shows ho- 
mology/identity (o~ chain) or a high degree of homology (/~ 
chain) at the amino acid level with the NH2 termini of the 
VNR a  chain (for OFA or) and platelet gpl 1  la (for OFA/3). 
Differences in NH2-terminal amino-acid sequence of the/3 
chain may be because of species differences, the OFA se- 
quence being of primate (Vero monkey) origin whereas the 
published sequence ofVNR/~ (Fitzgerald et al., 1987a; Rosa 
et al.,  1988) comes from studies of human tissue; however, 
the possibility of a second gpllla-like ~ chain cannot be ex- 
cluded. Finally, the tissue distribution in vivo of OFA and 
Davies eta|. Integrin Receptor of Osteoclasts  1823 Table L Comparison of  lmmunohistological Reactivity of  Anti-OFA, Anti-placental VNR, and gp  l 1  l a Antibodies 
Anti-OFA  a  Chain  Rabbit  Anti-melanoma VNR  Integrin f13 
Rabbit/Rat*  antiplacental  mAbs LMI42 and  gpl 1  la mAb 
Tissue  mAb23C6  mAbl3C2  Anti-OFA  VNR§  LM609  VI-PL2 
Human osteoclasts  + + +  + +  +  + +  + +  + + +  + + + 
Human osteoblasts  ...... 
Human bone marrow  ...... 
Human kidney 
Glomerulus  +  +  +  +  +  + 
Tubules  +  +  +  4-  +  - 
Vero monkey kidney 
cell line  + +  + +  nt¶  nt  + +  - 
Placenta  +  + +  nt  nt  + +  - / + 
Cultured  HUVE  + +  + +  nt  nt  + +  + + 
Vascular  endothelium  +  4-  nt  nt  nt  + 
Osteosarcoma cell linesll  -- / 4-  -/4-  nt  nt  - / 4-  - 
Animal osteoclasts 
Rabbit  +  +  +  +  +  +  -  -  +  +  +  - 
Chicken  + + +  -  -  4-  nt  - 
(Platelets  +) 
Immunohistological reactivity is scored from + + +  (strongly positive) to -  (negative) by comparison with appropriate positive and negative control antibodies 
for each tissue. 
nt,  not tested. 
HUVE,  Human umbilical vein endothelium. 
* Other tissues,  tested in human and rabbit (Horton and Chambers,  1986) with 23C6 and  13C2, are all negative by immunohistology. 
* Tested against formalin-fixed, wax-embedded tissues.  Reactivity predominantly  against ~x chain by Western blotting (See Fig. 6). 
§ Suzuki et al.  (1986). 
II Low levels seen by immunofluorescence confirmed by immunoprecipitation (data not shown). 
¶ Reactive by Western blot analysis;  see Fig.  6. 
VNR, as determined by immunohistological techniques (Figs. 
1 and 8, Table I) using anti-OFA mAbs 13C2 and 23C6 (Hor- 
ton et al.,  1985b),  LM142 and LM609 mAbs to melanoma 
VNR (Cheresh and Harper,  1987; Cheresh and Spiro,  1987) 
and heterosera to OFA and placental  VNR  (Suzuki  et al., 
1986)  is identical  for the two molecules. 
Two further lines of evidence support our contention that 
OFA and VNR are closely related,  or identical,  molecules. 
First,  epitope analysis (Nesbitt,  S., and M.  Horton, manu- 
script in preparation) has shown that anti-OFA monoclonal 
23C6 and antimelanoma VNR antibody LM609 are directed 
against  an  identical  antigenic  site  on  both  OC  and  mela- 
noma receptors. Second, a rabbit polyclonal antiserum made 
against  a  synthetic  peptide  corresponding  to  the  COOH- 
terminal  9  aminoacids,  C-ENGEGNSET,  of the published 
cDNA sequence of the VNR c~ chain (Suzuki et al.,  1987) 
shows an identical immunological reactivity profile to anti- 
bodies  13C2 and 23C6;  further,  the antiserum immunopre- 
cipitates both purified placental VNR  (Pytela et al.,  1987) 
and  Vero OFA and  an  identically  sized dimer from osteo- 
clastoma tumor (Horton, M., and S. Nesbitt, manuscript in 
preparation). 
The data presented in this paper are, thus, compatible with 
OFA being identical, or at least highly related, to the previ- 
ously  described  integrin  receptor,  VNR  (Pytela  et  al., 
1985b;  Suzuki et al.,  1987;  Fitzgerald  et al.,  1987b).  The 
VNR is a member of a gene family that has been divided into 
three subsets according to the type of the shared fl chain used 
(Hynes, 1987). One chain (ill) defines the fibronectin recep- 
tor and the very late antigens, VLA1 to 6, of lymphocytes and 
some other tissues (Hemler, 1988; Takada et al.,  1987; Son- 
nenberg et al.,  1987). f12 is restricted to leucocytes as the in- 
variant chain (or CD18 antigen; see Hogg and Horton,  1987, 
for relevant CD nomenclature) of the LFA-1 (CD1 la), Mac-1 
(CDI1b)  and  gp150/95  (CDllc)  antigens  (Springer  et al., 
1987). The third group has platelet gp111a as its fl(fl3) chain 
(Hynes,  1987;  Phillips et al.,  1988;  Ginsberg et al.,  1988) 
and includes the VNR and the gpllb/11 la complex, the latter 
being largely restricted to platelets.  As with the other inte- 
grin a  and fl chains,  OFA/VNR a  and fl show a  moderate 
degree of NH2-terminal amino acid homology with the other 
members of the gene family (see Fig. 7, legend and Results). 
This study has highlighted some points relating to the bio- 
chemistry  of VNR.  First,  two  low  molecular mass chains 
(c~), derived from the higher molecular mass component of 
the heterodimer (the a  chain) are frequently observed in our 
studies  using  immunoprecipitation  with  13C2/23C6  mAbs 
from Vero cells. This contrasts with previous reports on the 
structure of VNR where only one od chain has been observed 
(Pytela  et al.,  1985b;  Cheresh  and  Harper,  1987),  but  is 
similar to the finding of Sonnenberg et al. (1987) on the anal- 
ogous platelet gpIc'- 1  la complex (now termed VLA-6) where 
two  gpIc'-derived  light  chains  are  observed.  Variation  in 
glycosylation pattern (J.  Davies, unpublished  observations) 
does not seem to account for these differences as tunicamycin 
or endoglycosidase treatment fails to eliminate the disparity 
in molecular size.  It is possible that it represents a  species 
or tissue difference, the majority of our biochemical studies 
being carried out using a monkey kidney cell line, with dif- 
ferences in protein sequence of the Vero-derived OFA/VNR 
0¢ chain possibly occurring outside the region sequenced  in 
this paper, and could account for the observations. A further 
possibility is that the production of light chains of two sizes 
could result from the use of minor extra proteolytic cleavage 
sites in the o~ chain as have been reported for gpl lb (Loftus 
et al.,  1988), differential c¢ chain mRNA splicing (Suzuki et 
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lax size and structure in the VNR/OFA heterodimer. The rap- 
idly increasing complexity of the integrin superfamily makes 
the existence of further VNR-like chains a real possibility. 
The question arises as to the role of an integrin receptor 
(OFA/VNR) in bone? Two key observations provide clues as 
to its possible function. First, antibodies to the receptor can 
inhibit bone resorption and osteoclastic motility (Chambers 
et al.,  1986) in a manner similar to the hormone calcitonin 
(Chambers and Magnus, 1982); this strongly suggests the in- 
volvement of an OFA-ligand interaction in the regulation of 
bone resorption.  Second,  the tissue distribution of OFA in 
bone is restricted to mature OCs (Horton et al., 1985b; Hor- 
ton and Chambers,  1986)  and their  immediate  precursors 
during embryonic development and adult life (Simpson and 
Horton,  1989). This points to a function involving recogni- 
tion of a developmentally regulated protein ligand of specific 
segregation to bone; this might influence OC precursor hom- 
ing, differentiation,  fusion, and/or OC cellular adhesion to 
organic matrix of bone (and, vide infra, cell function in bone 
resorption). Vitronectin is a serum protein and not a promi- 
nent  component bone,  at least  at an  immunological  level 
(Horton,  M.,  unpublished  observations;  Hayman  et  al., 
1983).  Data  from  Cheresh  and  Spiro  (1987)  showed  that 
VNR had a wider ligand binding specificity  than originally 
reported (Pytela et al.,  1985b); this suggests that OFA/VNR 
in bone could recognize an alternative protein to vitronectin. 
A candidate ligand for VNR with a tissue distribution limited 
to bone is osteopontin (Oldberg et al.,  1986). It (a) contains 
the concensus Arg-Gly-Asp recognition sequence (Piersch- 
bacher and Ruoslahti,  1984) common to the ligands of the 
majority of integrin receptors (Ruoslahti and Pierschbacher, 
1987) including VNR (and OFA; this paper); (b) is synthe- 
sized by osteoblasts (Mark et al., 1987); (c) regulated by cal- 
citropic factors (Prince and Buffer,  1987; Noda et al.,  1988); 
(d) is found by in situ mRNA hybridization in bone anlagen 
just before OC  invasion  (Nomura et al.,  1988)  and is ex- 
pressed at the two other sites, placenta and kidney (Nomura 
et al.,  1988) where high density OFA/VNR is localized (this 
paper; Horton et al.,  1985b); and (e) can mediate cell adhe- 
sion (of fibroblasts) (Somerman et al.,  1987). 
Preliminary  analysis  of the  cellular  proteins  capable  of 
binding osteopontin-derived synthetic RGD-containing pep- 
tides  (Davies,  J.,  unpublished  observations)  demonstrates 
that a heterodimer with the characteristics  of OFA/VNR is 
capable of acting as a receptor for osteopontin. Whether os- 
teopontin  is the natural ligand for OFA/VNR  in vivo and 
what the exact role of such an interaction might be is cur- 
rently under investigation. For example, can RGD-containing 
peptides and bone proteins influence OC differentiation and 
resorptive activity  in vitro? 
In this paper we report on the structure of a cell surface 
molecule,  OFA,  which is expressed  at high levels by OCs 
(and some other tissues) and exhibits extensive homology/ 
identity to the previously described integrin receptor VNR 
(Pytela et al.,  1985b; Suzuki et al.,  1987; Fitzgerald et al., 
1987b).  Previous functional studies using anti-OFA mono- 
clonal antibodies (Chambers et al.,  1986) point to a role for 
OFA in the regulation of bone resorption.  The importance 
of OFA/VNR, and possibly other integrins and their ligands, 
in  normal  bone  development  and  function,  or  indeed  in 
pathogenesis of bone disease, remains to be fully evaluated. 
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